|
|
Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Case-Control Study
|
ZIA CP000185-10318
|
$27,190
|
$27,190
|
Abnet, Christian
|
DCEG (NCI)
|
|
|
The Golestan Cohort Study
|
ZIA CP000185-10361
|
$137,842
|
$137,842
|
Abnet, Christian
|
DCEG (NCI)
|
|
|
Randomized Placebo-Controlled Trial of a Gastrin Receptor Antagonist in Barretts Esophagus
|
5R03CA186218-02
|
$81,186
|
$81,186
|
ABRAMS, JULIAN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-03
|
$387,195
|
$387,195
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-02S1
|
$400,000
|
$60,000
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-03
|
$737,200
|
$110,580
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
1R44CA203336-01
|
$299,985
|
$299,985
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
|
(PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
|
4R01CA180149-04
|
$560,735
|
$560,735
|
AGUS, DAVID
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
1R01CA197081-01A1
|
$440,786
|
$295,327
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
APC Tumor Suppressor in Cell Differentiation and Death
|
3R01CA105038-10S1
|
$50,000
|
$50,000
|
AHMED, YASMATH
|
DARTMOUTH COLLEGE
|
|
|
Prospective Study of Human Oral Microbiome and Pancreatic Cancer Risk
|
5R01CA164964-03
|
$533,275
|
$533,275
|
AHN, JIYOUNG
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
|
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
|
5R01CA185357-03
|
$470,355
|
$470,355
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Elucidating the role and regulation of epithelial plasticity in metastasis
|
5F31CA177163-03
|
$30,341
|
$30,341
|
AIELLO, NICOLE
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction
|
4R01CA172741-04
|
$279,793
|
$279,793
|
AJANI, JAFFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
Role of Nix in pancreatic ductal adenocarcinoma
|
1F30CA200240-01A1
|
$33,371
|
$33,371
|
ALAGESAN, BRINDA
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
|
ATBC Study
|
ZIA CP010195-03031
|
$1,193,520
|
$179,028
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-08S1
|
$244,135
|
$29,296
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-08S2
|
$124,997
|
$15,000
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-08S3
|
$109,572
|
$13,149
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
3P30CA138313-08S4
|
$104,650
|
$12,558
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
|
Medical University of South Carolina - Cancer Center Support Grant
|
5P30CA138313-08
|
$2,093,000
|
$251,160
|
ALBERG, ANTHONY
|
MEDICAL UNIVERSITY OF SOUTH CAROLINA
|
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-03
|
$1,295,865
|
$194,380
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
|
Mesothelin-targeted immunotoxins in Pancreatic Cancer
|
ZIA BC 011652
|
$437,407
|
$437,407
|
Alewine, Christine
|
CCR (NCI)
|
|
|
Clinical Support
|
ZIE BC 011653
|
$23,021
|
$6,906
|
Alewine, Christine
|
CCR (NCI)
|
|
|
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
|
5R01CA177993-03
|
$590,158
|
$590,158
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
INFLAMMATORY CHEMOKINE CCL3 IN THE TUMOR MICROENVIRONMENT LEADS TO ENHANCED ANTITUMOR IMMUNE DEVELOPMENT IN THE DRAINING LYMPH NODE
|
5F31CA192874-03
|
$31,560
|
$31,560
|
ALLEN, FREDERICK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
|
5R01CA182076-03
|
$349,513
|
$349,513
|
ALLEN, PETER
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-02
|
$384,048
|
$384,048
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN
|
|
|
MYC is a critical downstream effector in KRAS-driven pancreatic cancer
|
5F32CA192769-02
|
$58,002
|
$58,002
|
ALLEN-PETERSEN, BRITTANY
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
|
Novel Strategies for Precision T-cell Therapies
|
1R01CA198095-01A1
|
$520,564
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-47S1
|
$142,498
|
$1,425
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-47
|
$2,645,581
|
$26,456
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
NCTN Deep South Research Consortium
|
5U10CA180855-03
|
$497,800
|
$49,780
|
ALVAREZ, RONALD
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition
|
4R01CA169134-04
|
$312,942
|
$312,942
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$791,464
|
$158,293
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
|
High Resolution Microendoscopy for the Management of Esophageal Neoplasia
|
5R01CA181275-03
|
$587,321
|
$587,321
|
ANANDASABAPATHY, SHARMILA
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy
|
5R01CA182872-03
|
$628,483
|
$628,483
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
|
Bitter Melon Component and Colon Cancer Prevention
|
5R01CA190291-03
|
$544,710
|
$544,710
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
|
Whole exome sequencing of oropharyngeal carcinoma (OPX-WES)
|
5R03CA183010-02
|
$56,500
|
$56,500
|
ANANTHARAMAN, DEVASENA
|
INTERNATIONAL AGENCY FOR RES ON CANCER
|
|
|
Women's Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-04S1
|
$170,764
|
$30,738
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Relationships between guideline-concordant treatment and survival following an endometrial cancer diagnosis in the Life and Longevity After Cancer Study
|
3UM1CA173642-04S2
|
$116,303
|
$20,935
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Women's Health Initiative Cancer Survivor Cohort
|
4UM1CA173642-04
|
$2,396,733
|
$431,412
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-03
|
$541,578
|
$81,237
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
3U54CA132384-07S1
|
$199,986
|
$143,990
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132384-07
|
$1,082,983
|
$779,748
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
|
REVERSING CELLULAR IMMORTALITY IN CANCER
|
3R35CA197563-01S1
|
$10,658
|
$7,461
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
|
Reversing Cellular immortality in cancer
|
3R35CA197563-02S1
|
$18,652
|
$13,056
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
|
Reversing Cellular immortality in cancer
|
5R35CA197563-02
|
$972,569
|
$680,798
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
|
T Cell Alternative p38 Activation Pathway
|
ZIA BC 010774
|
$555,989
|
$277,995
|
Ashwell, Jonathan
|
CCR (NCI)
|
|
|
Cancer Center Support Grant
|
3P30CA082103-18S1
|
$121,856
|
$10,967
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Total relevant funding to Digestive Diseases for this search: $502,916,313
|
